Aratana Therapeutics Inc. (NYSE: PETX) said that post-licensing marketing studies of canine lymphoma products AT-004 and AT-005 will not fully capture market opportunities. The stock price plummeted $6.82 to close at $10.67.
Aratana Therapeutics says no benefit to post-licensing marketing studies
September 25, 2015 at 20:56 PM EDT
